ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed malignancy, meeting 1 of the following criteria: * Solid tumor that is refractory to ≥ 1 line of standard treatment OR for which no standard therapy is available * Must have ≥ 1 lesion amenable to percutaneous biopsy (for solid tumor patients enrolled after the initial phase of the study) * Chronic lymphocytic leukemia (CLL) or follicular lymphoma with no current indication for standard therapy OR disease that has failed ≥ 1 line of standard therapy * No disease-associated symptoms requiring immediate therapy or other interventions * Must be willing to undergo tumor biopsies\* after the initial phase of the study NOTE: \*Patients with CLL undergo peripheral blood collection instead of biopsy * No primary brain tumors, brain metastases, or leptomeningeal disease PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-2 or Karnofsky PS 60-100% * Life expectancy ≥ 3 months * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9 g/dL * Bilirubin \< 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * Creatinine \< 1.5 times ULN OR creatinine clearance ≥ 60 mL/min * INR ≤ 1.4 * PTT ≤ 36 seconds * Calcium (corrected) normal * Magnesium \< 1.5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 30 days after study completion * No history of seizures * No evidence of bleeding diathesis * No uncontrolled intercurrent illness including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmias * No psychiatric illness or social situations that would limit study compliance PRIOR CONCURRENT THERAPY: * At least 2 weeks since prior radiation therapy or surgery and recovered * At least 2 weeks since other prior therapy and recovered * No concurrent antiretroviral therapy for HIV-positive patients * No concurrent lung, liver, or mediastinal lymph node biopsies * No other concurrent investigational agents